Does Finasteride Affect Ejaculation?
Yes, finasteride definitively affects ejaculation, causing decreased ejaculate volume in approximately 3.7% of patients and ejaculation disorders in 0.8% during the first year of treatment, with these effects being dose-dependent and potentially reversible upon discontinuation. 1
Specific Ejaculatory Effects
The FDA label for finasteride clearly documents multiple ejaculatory adverse effects 1:
- Decreased ejaculate volume: 3.7% (vs 0.8% placebo) in year 1
- Ejaculation disorder: 0.8% (vs 0.1% placebo) in year 1
- Abnormal ejaculation: 7.2% with finasteride monotherapy, rising to 14.1% when combined with doxazosin in the MTOPS study 1
The volume reduction is approximately 11% (0.3 mL decrease) and represents the most consistently documented sexual side effect of finasteride 2. This volume decrease does not appear to interfere with normal sexual function or fertility, as sperm concentration, total sperm count, motility, and morphology remain unaffected 2.
Clinical Context from Guidelines
The 2023 European Association of Urology guidelines confirm that 5α-reductase inhibitors like finasteride cause ejaculation disorders including "retrograde ejaculation, ejaculation failure, or decreased semen volume" 3. The 2021 AUA guidelines similarly note that ejaculatory function declines more pronouncedly with finasteride compared to placebo 4.
Time Course and Reversibility
Critical clinical point: In years 2-4 of treatment, ejaculation disorders decreased to 0.2% (vs 0.1% placebo), and decreased ejaculate volume persisted at only 1.5% (vs 0.5% placebo) 1. This suggests either tolerance development or patient adaptation over time.
Upon discontinuation, effects reverse within approximately 2 weeks as DHT levels return to baseline 1.
Comparative Risk Profile
Recent pharmacovigilance data from 2024 identified finasteride as the medication most commonly associated with painful ejaculation (150 events, 7.8%) and ejaculation failure (735 events, 38.4%) across FDA and European databases 5. This disproportionate reporting may reflect both actual incidence and heightened awareness following post-finasteride syndrome discussions.
Patient Counseling Requirements
The FDA mandates that physicians inform patients that ejaculate volume may decrease during treatment but this does not interfere with normal sexual function 1. However, patients should be counseled that ejaculation disorders can occur and to report any concerning changes.
Common Pitfall
Do not confuse decreased ejaculate volume (common, benign) with ejaculation failure or painful ejaculation (rare but more concerning). The volume decrease is physiologic due to reduced prostatic secretions and does not indicate pathology or fertility impairment 2.